Zimmer Biomet Holdings, Inc.

NYSE:ZBH

Medical - Devices

Healthcare
$103.32 +1.00%

+$0.87 today

Market cap
$19.55B
Beta
0.47
P/E (TTM)
22.5
EPS (TTM)
$3.90
Dividend yield
1.09%
52W Low $79.12High $108.29

Volume 2.34M

Average 2.28M

ZBH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Zimmer Biomet Holdings, Inc.NYSE: ZBH

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $24.6M rose 16.0% year over year, ahead of the +13.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at -4.9% a year.

Context

  • Stock-based compensation amounted to 1.1% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.0% holds above the trailing-twelve-month pace of +13.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$24.6M+1.7% QoQ
Last fiscal yearDec 2025
$90.2M-10.7% YoY
LTMJun 2026
$98.2M+13.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.0%——
1 year-10.7%——
3-year CAGR-4.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
90.2M USD
Year-over-year change
-10.7%
4-year CAGR
+4.4%

Stock-Based Compensation vs competitors

How ZBH compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.7% is the 4th highest of 10, against a peer median of +7.5%.
  • Stock-based compensation amounts to 1.2% of revenue for ZBH, versus a peer median of 1.0%.
ZBH Competitors
Stock-Based Compensation for ZBH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$496M USD+14.8%+8.8%1.3%
SYKStryker CorporationLTM Jun 2026$251M USD+9.6%+13.1%1.0%
ALGNAlign Technology, Inc.LTM Jun 2026$185.87M USD+111.5%+11.7%4.5%
EWEdwards Lifesciences CorporationLTM Jun 2026$168M USD-1.5%+7.6%2.6%
BSXBoston Scientific CorporationLTM Jun 2026$166M USD+5.7%+10.8%0.8%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$118M USD+6.3%+24.7%0.6%
PHGKoninklijke Philips N.V.LTM Jun 2026€112M EUR-17.6%—0.6%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$98.2M USD+13.7%-4.9%1.2%
SNNSmith & Nephew plcFY2025$43M USD+7.5%+2.4%0.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M USD+40.4%+15.9%5.1%
Peer median (excluding ZBH) —+7.5%+11.2%1.0%

Competitors are the stored peer set for ZBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income445.5M291.2M1.03B905.2M705.1M
Depreciation & Amortization937.7M926.4M951.7M996.3M1.09B
Deferred Income Tax(102.1M)(64.4M)(96.3M)(47.7M)(87.2M)
Stock-Based Compensation76M105M99.8M101M90.2M
Change in Working Capital(134.2M)(311.4M)(396.2M)(455.4M)(104.9M)
Accounts Receivables(40.8M)(184.7M)(51.9M)(89.7M)(127.3M)
Inventory(8.4M)(75.6M)(240.4M)49.9M98.2M
Accounts Payables86.5M103M(55.3M)(322M)101.8M
Other Working Capital(171.5M)(154.1M)(48.6M)(93.6M)(177.6M)
Other Non-Cash Items276.3M337.9M(2.5M)0100K
Operating Cash Flow1.5B1.28B1.58B1.5B1.7B
Capital Expenditures(152M)(217.6M)(394.5M)(356.8M)(224.5M)
Acquisitions (Net)0(99.8M)(134.9M)(276.3M)(1.39B)
Purchases of Investments(273.6M)(258.3M)(311.7M)(240.3M)(300.5M)
Sales of Investments1.9M89.4M33.4M22.1M0
Other Investing Activities(88.3M)(72.6M)(74.6M)(189.8M)(57.5M)
Investing Cash Flow(503.6M)(529.2M)(778.9M)(888.1M)(1.98B)
Debt Repayment(1.06B)(1.06B)54.6M536.3M1.03B
Common Stock Issued122.5M00039.7M
Common Stock Repurchased0(126.4M)(692.2M)(868M)(487M)
Dividends Paid(200.1M)(201.2M)(200.9M)(196M)(190.3M)
Other Financing Activities(173.4M)544.5M75M43.2M(65.5M)
Financing Cash Flow(1.31B)(843.8M)(763.5M)(484.5M)326M
Effect of Forex Changes(13.2M)(14.5M)900K(17.1M)19M
Net Change in Cash(323.6M)(102.8M)40.1M109.7M66.4M
Free Cash Flow1.35B1.07B1.19B1.14B1.47B

Zimmer Biomet Holdings, Inc.

NYSE:ZBH

Intrinsic Alpha fair value

Locked

Current Price

$103.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.